-
According to a study published in the journal Cancer Research the diabetes drug metformin assists in shrinking breast-cancer tumors when combined with the chemotherapy drug doxorubicin more effectively than if the chemotherapy had been given alone. The drugs also stopped the tumors from returning and researchers reported that stem cells were killed as well as regular cancer cells. Mice with the br
제약단신
메디칼라이터팀
2009.09.15 00:00
-
A federal judge in the first jury trial involving Merck"s bone drug Fosamax declared a mistrial after the jurors were unable to reach a verdict with one holdout juror accusing others of intimidation. The case, involving a patient who had taken the drug from 1997-2006 and who subsequently developed osteonecrosis, is whether Merck knew or should have known that Fosamax can cause osteonecrosis of th
제약단신
메디칼라이터팀
2009.09.15 00:00
-
In a late-stage trial that compared a combination of aflibercept and the chemotherapy drug Gemzar [gemcitabine] to Gemzar and a placebo it was shown that the aflibercept group was not surviving much longer than the placebo group. The drug candidate has been developed by Sanofi-Aventis and Regeneron Pharmaceuticals Inc. In the study it is being tested in patients with pancreatic cancer that has met
제약단신
메디칼라이터팀
2009.09.15 00:00
-
The FDA has approved Theravance Inc. and Astella Pharma Inc."s Vibativ [telavancin], a once-daily infusion antibiotic to treat difficult skin infections such as methicillin-resistant Staphylococcus aureus, or MRSA. It will come with a "black- box" warning for pregnant women.
제약단신
메디칼라이터팀
2009.09.14 00:00
-
A single intravenous dose of the experimental drug, peramivir cured flu symptoms with the same efficacy as five days of Tamiflu pills according to a study in Asia. The study was presented at the American Society for Microbiology conference in California which is the first conference of infectious disease experts since the emergence of H1N1 in April. Currently treatment options are receiving atten
제약단신
메디칼라이터팀
2009.09.14 00:00
-
According to Nancy Cox, director of the flu division at the US Centers for Disease Control and Prevention in Atlanta H1N1 vaccinations may commence in the first week of October after a single dose has found been found to produce immunity in 8-10 days. HHS Secretary Kathleen Sebelius is confident there will be enough vaccine available and also says that it will be available earlier than expected. T
제약단신
메디칼라이터팀
2009.09.14 00:00
-
인간면역결핍바이러스(HIV)로 인해 가장 극심한 피해를 받고 있는 아프리카에서 HIV 백신 개발에 대한 새로운 가능성이 제시됐다. 미국 스크립스연구센터(Scripps Research Institute) 데니스 버톤(Dennis Burton) 박사팀은 HIV에 감염된 아프리카 환자들을 대상으로 혈청 검사를 실시, HIV를 공격하는 항체인 PG9, PG16을 발견했다. 전문가들은 아직까지 HIV에 대한 명확한 치료법이 없고 이제까지의 백신 개발들이 거의 다 실패로 돌아간 상황에서 이 항체들이 타개책이 될 수 있을 것이라고 전망하고 있다. 연구팀은 약 1800명의 HIV-1 감염환자들의 혈청을 검사해 HIV를 공격하는 항체들을 찾았고, 버톤 박사는 "이번 발견이 최근 10년여의 기간동안 분류된 최초의 HIV 항
제약단신
임세형 기자
2009.09.14 00:00
-
국내를 포함해 세계적으로 고령화가 이슈가 되고 있는 가운데 치매에 대한 비중도 같이 높아지고 있다. 하지만 치매에 대해서는 주요한 치료방법은 아직 나와있지 않다. 이런 상황에서 치매의 주요 원인 중 한 가지로 꼽히는 알츠하이머병(Alzheimer`s disease)과 연관된 유전자가 추가적으로 밝혀졌다는 사실은 치매 치료에 새로운 전기가 되고있다. 2개의 대규모 유전자 분석연구를 통해 밝혀진 알츠하이머병 관련 유전자는 "CLU(APOJ)". "CR1". "PICALM"다. 전문가들은 이 유전자들이 알츠하이머병의 주요한 유전자로 밝혀진 "apolipoprotein E(APOE)" 이후 약 15년 동안 가장 중요한 요소들로 꼽고 있다.영국 카디프대학(Cardiff University) 줄리에 윌리
제약단신
임세형 기자
2009.09.14 00:00
-
예방접종의 안전성과 필요성으로 논란이 됐던 인간유두종바이러스(HPV) 백신인 미국 머크(Merck)사의 가다실(Gardasil)이 미국식품의약국(FDA) 자문위원회로부터 남성 접종에 대한 안전성 평가에서 긍정적인 점수를 얻었다. 이와함께 자문위는 GSK(GlaxoSmithKlien)의 HPV 백신인 써바릭스(Cevarix)의 안전성에도 합격점을 줘 미국 내 HPV 백신의 적용범위와 선택의 폭을 넓히는데 무게를 실었다. 가다실은 2006년 9~26세의 여성에게 HPV 6, 11, 16, 18형에 대한 자궁경부암 예방백신으로 승인받았다. 이후 머크사는 가다실의 적응증을 9~26세 남성들의 HPV 6, 11형 예방까지 확대하기 위해 노력해왔다. 회의 전 머크사는 자료를 FDA에 제출해 효과와 안전성을 인정받았고,
제약단신
임세형 기자
2009.09.14 00:00
-
신종인플루엔자(신종플루) 사망자가 8월까지 2837명에 도달한 가운데 전문가들이 우려해온 "더 강력한 신종플루"는 아직 보이지 않고 있다고 세계보건기구(WHO)가 밝혔다.미국질병예방관리센터(CDC)도 "아직 신종플루로 인한 증상들이 대부분 경증에 머물고 있다"고 발표해 WHO의 의견에 힘을 실었다. 하지만 여전히 신종플루의 잠재적인 위험성과 계절성 인플루엔자에 대한 경각심도 늦춰서 안된다고 강조했다. CDC는 "신종플루가 더 치명적인 증상을 띄지 않고 있다는 점은 개발되고 있는 백신들이 유효할 수 있다는 근거가 된다"며 현재의 상황에 긍정적인 반응을 보였다. 또한 치료제로 사용되고 있는 오셀타미비어(oseltamivir, Tamiflu)와 자나미비어(zanamivir, Relenza)에 대한 내성사례들이
제약단신
임세형 기자
2009.09.14 00:00
-
The FDA has approved Generex Biotechnology Corp.’s drug candidate Generex Oral-lyn for experimental use in diabetic patients with dangerous illnesses who don"t have a satisfactory treatment. In order for such drugs to be given experimental approval they must demonstrate a prospect of efficacy and this drug treats diabetes by being delivered through the lining of the mouth.
제약단신
메디칼라이터팀
2009.09.13 00:00
-
The FDA has removed its hold on clinical trials of Dynavax’s hepatitis B vaccine candidate HEPLISLAV which have been stopped for a year and a half following one patient in a trial being diagnosed with a rare disease that causes inflammation of the blood vessels. HEPLISLAV is being designed to provide better protection in two doses rather than the current vaccine’s three dose system. The company pl
제약단신
메디칼라이터팀
2009.09.13 00:00
-
Shire"s Gaucher disease drug velaglucerase alfa, which was rushed to market a year earlier because of Genzyme Corp.’s manufacturing disruption, could take a 15 percent of the $1.1 billion market by 2012 as well as earning $50 million in 2010. Shire has submitted a safety plan to the FDA allowing the drug to be available whilst Genzyme continues to make its new supply.
제약단신
메디칼라이터팀
2009.09.13 00:00
-
Abbott, which has a 10 percent stake in Evalve, will pay as much as $410 million for its acquisition in a deal that will give Abbott a presence in the field of non-surgical treatments for heart disease according to John Capek, the company"s executive vice president for medical devices. Evalve is currently testing the MitraClip system which is used to treat mitral regurgitation without the need fo
제약단신
메디칼라이터팀
2009.09.13 00:00
-
Paul Pomerantz, MBA, CAE, will become DIA’s worldwide executive director effective December 1, 2009 after he transitions from his current postion as executive vice president of the American Society of Plastic Surgeons (ASPS).
제약단신
메디칼라이터팀
2009.09.13 00:00
-
Results from trials of the new swine flu vaccine that were conducted by CSL Limited, an Australian firm, indicate that one vaccine is enough to give protective immunity in adults. The results were published in the New England Journal of Medicine and indicate that much less vaccine is now required to innoculate the 159 million people that the Centers for Disease Control and Prevention estimate are
제약단신
메디칼라이터팀
2009.09.13 00:00
-
Results have been published in the New England Journal of Medicine from a current study of 9 patients with relapsing-remitting multiple sclerosis who were taking Tysabri. They were tested at three, six, 12, and 18 months after starting treatment for the JC virus. The virus has been linked to the brain disorder, progressive multifocal leukoencephalopathy (PML) where it defeats immune defenses, muta
제약단신
메디칼라이터팀
2009.09.11 00:00
-
A judge will not dismiss 24 claims from plaintiffs that Fosamax causes osteonecrosis of the jaw, or ONJ saying whether there is a three-year threshold for developing ONJ is an issue for to be debated in court. Robert Marx, an expert for the plaintiffs has said that Fosamax doesn"t cause ONJ in patients who take the drug for less than a three-year period so will not be permitted to testify but tw
제약단신
메디칼라이터팀
2009.09.11 00:00
-
German drug and chemical maker Merck KGaA has purchased Suzhou Taizhu Technology Development Co. Ltd., a Chinese pigment company, euro28 million ($40 million). The purchase includes the production site in Taicang as well as its entire sales and marketing organization.
제약단신
메디칼라이터팀
2009.09.11 00:00
-
An FDA panel has voted in favor of GlaxoSmithKline PLC"s vaccine Cervarix endorsing that it is safe and effective for girls and young women protecting against two strains of HPV that are linked to around 70 percent of cervical cancer cases in the US. The review of the March 2007 application has been delayed as the FDA examined the safety of the drug including a higher number of young women who re
제약단신
메디칼라이터팀
2009.09.11 00:00